References
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
- Council for International Organizations of Medical Sciences in collaboration with the World Health Organization. International ethical guidelines for health-related research involving humans; 2016. Available from: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf. Accessed May 21, 2021.
- European Union. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745. Accessed May 21, 2021.
- European Union. Regulation (EU) 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Available from: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF. Accessed May 21, 2021.
- Aldinger C, Bierer B, Li R, et al. MRCT center post-trial responsibilities framework continued access to investigational medicines. guidance document. Version 1.2; 2017. Available from: https://mrctcenter.org/wp-content/uploads/2017/12/2017-12-07-Post-Trial-Responsibilities-Guidance-Document-Version-1.2.pdf. Accessed May 20, 2021.
- Centre for Research on Multinational Corporations (SOMO). Post-trial access to treatment. Corporate best practices; 2015. Available from: https://www.somo.nl/wp-content/uploads/2015/02/Post-trial-access-to-treatment.pdf. Accessed May 18, 2021.
- Guru A, Post RJ, Ho YY, Warden MR. Making sense of optogenetics. Int J Neuropsychopharmacol. 2015;18(11):pyv079. doi:10.1093/ijnp/pyv079
- Keshmiri Neghab H, Soheilifar MH, Grusch M, et al. The state of the art of biomedical applications of optogenetics. Lasers Surg Med. 2021. doi:10.1002/lsm.23463
- Liu S, Tang Y, Xing Y, Kramer P, Bellinger L, Tao F. Potential application of optogenetic stimulation in the treatment of pain and migraine headache: a perspective from animal studies. Brain Sci. 2019;9(2):26. doi:10.3390/brainsci9020026
- Wykes RC, Kullmann DM, Pavlov I, Magloire V. Optogenetic approaches to treat epilepsy. J Neurosci Methods. 2016;260:215–220. doi:10.1016/j.jneumeth.2015.06.004
- Wang KW, Ye XL, Huang T, Yang XF, Zou LY. Optogenetics-induced activation of glutamate receptors improves memory function in mice with Alzheimer’s disease. Neural Regen Res. 2019;14(12):2147–2155. doi:10.4103/1673-5374.262593
- Gensight. Dose-escalation study to evaluate the safety and tolerability of GS030 in Subjects with Retinitis Pigmentosa (PIONEER). NLM identifier: NCT03326336. Available from: http://www.clinicaltrials.gov/ct2/show/NCT03326336. Accessed December 1, 2021.
- Allergan. RST-001 phase I/II trial for advanced retinitis pigmentosa. NLM identifier: NCT02556736. Available from: http://clinicaltrials.gov/ct2/show/NCT02556736. Accessed December 1, 2021.
- Nanoscope Therapeutics Inc. Efficacy and safety of vMCO-010 optogenetic therapy in adults with retinitis pigmentosa (RESTORE). NLM identifier: NCT04945772. Available from: https://clinicaltrials.gov/ct2/show/NCT04945772. Accessed December 1, 2021.
- Nanoscope Therapeutics Inc. Dose-escalation study to evaluate the safety and tolerability of intravitreal vMCO-I in patients with advanced retinitis pigmentosa. NLM identifier: NCT04919473. Available from: https://clinicaltrials.gov/ct2/show/NCT04919473. Accessed December 1, 2021.
- Sahel JA, Boulanger-Scemama E, Pagot C, et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med. 2021;27:1223–1229. doi:10.1038/s41591-021-01351-4
- Nanoscope therapeutics. Bedford, Texas: Press Release; 2021. Available from: https://nanostherapeutics.com/2021/06/03/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision/. Accessed November 30, 2021.
- Rapeaux AB, Constandinou TG. Implantable brain machine interfaces: first-in-human studies, technology challenges and trends. Curr Opin Biotechnol. 2021;72:102–111. doi:10.1016/j.copbio.2021.10.001
- Wheless JW, Gienapp AJ, Ryvlin P. Vagus nerve stimulation (VNS) therapy update. Epilepsy Behav. 2018;88:2–10. doi:10.1016/j.yebeh.2018.06.032
- Sadelain M. Insertional oncogenesis in gene therapy: how much of a risk? Gene Ther. 2004;11(7):569–573. doi:10.1038/sj.gt.3302243
- Zhang D, Chen Q, Shi C, et al. Dealing with the foreign‐body response to implanted biomaterials: strategies and applications of new materials. Adv Funct Mater. 2021;31(6):2007226. doi:10.1002/adfm.202007226
- Shen Y, Campbell RE, Côté DC, Paquet ME. Challenges for therapeutic applications of opsin-based optogenetic tools in humans. Front Neural Circuits. 2020;14:41. doi:10.3389/fncir.2020.00041
- Delbeke J, Haesler S, Prodanov D. Failure modes of implanted neural interfaces. In: Guo L, editor. Neural Interface Engineering: Linking the Physical World and the Nervous System. Cham: Springer; 2020:123–172.
- European Medicines Agency. Guideline on follow-up of patients administered with gene therapy medicinal products (EMEA/CHMP/GTWP/60436/2007). Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdf. Accessed May 25, 2021.
- European Medicines Agency. Guideline on safety and efficacy follow-up – risk management of advanced therapy medicinal products (EMEA/149995/2008). Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products_en.pdf. Accessed May 26, 2021.
- Drew L. “Like taking away a part of myself”–life after a neural implant trial. Nat Med. 2020;26(8):1154–1156. doi:10.1038/d41591-020-00028-8
- Palmerini E. A legal perspective on body implants for therapy and enhancement. Int Rev Law Comp Technol. 2015;29(2–3):226–244. doi:10.1080/13600869.2015.1055664
- Fins JJ. Deep brain stimulation, deontology and duty: the moral obligation of non-abandonment at the neural interface. J Neural Eng. 2009;6(5):050201. doi:10.1088/1741-2552/6/5/050201
- Underwood E. Researchers grapple with the ethics of testing brain implants. Science. 2017. doi:10.1126/science.aar3698
- Rossi PJ, Giordano J, Okun MS. The problem of funding off-label deep brain stimulation: bait-and-switch tactics and the need for policy reform. JAMA Neurol. 2017;74(1):9–10. doi:10.1001/jamaneurol.2016.2530
- Lázaro-Muñoz G, Yoshor D, Beauchamp MS, Goodman WK, McGuire AL. Continued access to investigational brain implants. Nat Rev Neurosci. 2018;19(6):317–318. doi:10.1038/s41583-018-0004-5
- Sierra-Mercado D, Zuk P, Beauchamp MS, et al. Device removal following brain implant research. Neuron. 2019;103(5):759–761. doi:10.1016/j.neuron.2019.08.024
- Cho HL, Danis M, Grady C. Post-trial responsibilities beyond post-trial access. Lancet. 2018;391(10129):1478–1479. doi:10.1016/S0140-6736(18)30761-X
- Hendriks S, Grady C, Ramos KM, et al. Ethical challenges of risk, informed consent, and posttrial responsibilities in human research with neural devices: a review. JAMA Neurol. 2019;76(12):1506–1514. doi:10.1001/jamaneurol.2019.3523
- Lawton J, Blackburn M, Rankin D, et al. Broadening the debate about post-trial access to medical interventions: a qualitative study of participant experiences at the end of a trial investigating a medical device to support type 1 diabetes self-management. AJOB Empirical Bioethics. 2019;10(2):100–112. doi:10.1080/23294515.2019.1592264
- Saver RS. At the end of the clinical trial: does access to investigational technology end as well. W N Eng L Rev. 2009;31:411.
- Richardson HS, Belsky L. The ancillary-care responsibilities of medical researchers. An ethical framework for thinking about the clinical care that researchers owe their subjects. Hastings Cent Rep. 2004;34:25–33. doi:10.2307/3528248
- Gilbert F, Goddard E, Viaña JNM, Carter A, Horne M. I miss being me: phenomenological effects of deep brain stimulation. AJOB Neurosci. 2017;8(2):96–109. doi:10.1080/21507740.2017.1320319
- Leuenberger M, Klein E, Specker Sullivan L. Losing meaning: philosophical reflections on neural interventions and their influence on narrative identity. Neuroethics. 2021;1–15. doi:10.1007/s12152-021-09468-6
- Gilbert F, Viaña JNM, Ineichen C. Deflating the “DBS causes personality changes” bubble. Neuroethics. 2018;14:1–17.